Positively Aware Triumeq


DTG/ABC/3TC dolutegravir/abacavir/lamivudine

Recommended initial regimen for most people if HLA-B*5701 negative
Single-Tablet Regimen

Standard Dose

One tablet once daily, without regard to food, for people with no evidence of INSTI resistance. Tablet contains 50 mg of the INSTI dolutegravir plus 600 mg abacavir and 300 mg lamivudine. For adults and children weighing at least 88 pounds (40 kg). An additional 50 mg dose of dolutegravir (brand name Tivicay) separated by 12 hours from Triumeq is required for people who have INSTI drug resistance or are taking certain other medications.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney or liver problems. According to the drug label, Triumeq is not recommended for people who have decreased kidney function (creatinine clearance less than 30 mL/min) due to lamivudine component, or those with mild, moderate, or severe liver impairment due to abacavir component. This medication combination, however, is often used in reduced renal function below 30 mL/min, due to relatively minimal risk of lamivudine accumulation and side effects. In addition, alternative doses may be obtained by using the individual components of this medication as needed.
  • See the individual drugs contained in Triumeq: Tivicay, Ziagen, and Epivir.
  • See package insert for more complete information on potential side effects and interactions.


ViiV Healthcare
viivhealthcare.com; triumeq.com
(877) 844-8872



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments